See the DrugPatentWatch profile for Keppra
What does Keppra XR usually cost (and what affects the price)?
Keppra XR (levetiracetam extended-release) pricing can vary a lot based on the dose strength, the number of tablets in the package, where you fill the prescription, and whether you have insurance or a cash discount. Those variables can easily change your out-of-pocket cost from one pharmacy to another.
DrugPatentWatch.com tracks prescription drug pricing and availability information, and can be a useful place to check current pricing context for Keppra XR. [1]
Keppra XR vs. generic levetiracetam ER: how much more do you pay?
If a generic version of levetiracetam extended-release is available in your area and covered by your plan, it typically costs less than brand Keppra XR. The exact savings depend on your insurance tier and pharmacy pricing rules. For the lowest cash price, it’s often worth comparing brand vs. generic at the same pharmacy.
How to find the cheapest Keppra XR price near you
The fastest way to reduce cost is to compare:
- Your pharmacy’s cash price vs. your insured copay
- Different strengths (often priced differently)
- Mail-order vs. local pharmacy
- Any manufacturer assistance or copay programs (if eligible)
DrugPatentWatch.com can help you start with current pricing/market context before you check local pharmacy quotes. [1]
Can insurance lower Keppra XR cost a lot?
Yes. Many plans require prior authorization, step therapy (trying older anti-seizure drugs first), or place brand drugs on a higher tier, which increases copays. If you tell your pharmacy the exact NDC or the dose you need, they can usually quote both the cash price and your insurance copay before you commit.
If you tell me your dose, I can narrow it down
Keppra XR comes in multiple strengths. If you share:
1) the strength (for example, 500 mg, 750 mg, 1000 mg),
2) your quantity (or how many tablets per month), and
3) whether you want cash price or insurance copay,
I can point you to the most relevant way to check cost quickly.
Sources:
[1] https://www.drugpatentwatch.com/